share_log

William Blair Equities Analysts Increase Earnings Estimates for FibroGen, Inc. (NASDAQ:FGEN)

Defense World ·  Aug 12, 2022 02:31

FibroGen, Inc. (NASDAQ:FGEN – Get Rating) – Equities researchers at William Blair increased their Q3 2022 earnings per share estimates for shares of FibroGen in a note issued to investors on Monday, August 8th. William Blair analyst A. Hsieh now expects that the biopharmaceutical company will post earnings of ($0.58) per share for the quarter, up from their previous forecast of ($0.73). The consensus estimate for FibroGen's current full-year earnings is ($3.39) per share. William Blair also issued estimates for FibroGen's Q4 2022 earnings at ($0.55) EPS, FY2022 earnings at ($2.58) EPS, Q1 2023 earnings at ($0.53) EPS, Q2 2023 earnings at ($0.53) EPS, Q3 2023 earnings at ($0.52) EPS, Q4 2023 earnings at ($0.50) EPS, FY2023 earnings at ($2.07) EPS and FY2024 earnings at ($1.63) EPS.

Get FibroGen alerts:

FibroGen (NASDAQ:FGEN – Get Rating) last announced its earnings results on Monday, August 8th. The biopharmaceutical company reported ($0.78) earnings per share for the quarter, topping the consensus estimate of ($0.94) by $0.16. FibroGen had a negative return on equity of 100.51% and a negative net margin of 83.64%. The firm had revenue of $29.81 million for the quarter, compared to the consensus estimate of $36.15 million. During the same period in the previous year, the business earned ($1.45) EPS. The firm's revenue for the quarter was up 22.3% on a year-over-year basis.

FGEN has been the topic of several other reports. The Goldman Sachs Group dropped their target price on FibroGen from $9.00 to $8.00 and set a "sell" rating on the stock in a research note on Tuesday, May 24th. StockNews.com cut FibroGen from a "buy" rating to a "hold" rating in a research report on Wednesday.

FibroGen Price Performance

Shares of FGEN stock opened at $14.05 on Thursday. FibroGen has a 1-year low of $7.81 and a 1-year high of $16.91. The stock's fifty day moving average price is $11.72 and its 200 day moving average price is $12.01. The company has a market cap of $1.31 billion, a price-to-earnings ratio of -5.93 and a beta of 0.87.

Institutional Trading of FibroGen

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Point72 Asset Management L.P. lifted its position in FibroGen by 235.9% during the 4th quarter. Point72 Asset Management L.P. now owns 3,732,594 shares of the biopharmaceutical company's stock worth $52,630,000 after acquiring an additional 2,621,494 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank lifted its holdings in shares of FibroGen by 17.9% in the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 69,170 shares of the biopharmaceutical company's stock valued at $975,000 after buying an additional 10,521 shares during the period. Long Focus Capital Management LLC acquired a new position in shares of FibroGen in the 4th quarter valued at about $2,390,000. Fox Run Management L.L.C. acquired a new position in shares of FibroGen in the 4th quarter valued at about $231,000. Finally, Primecap Management Co. CA lifted its holdings in shares of FibroGen by 1.5% in the 4th quarter. Primecap Management Co. CA now owns 12,989,123 shares of the biopharmaceutical company's stock valued at $183,147,000 after buying an additional 197,366 shares during the period. Institutional investors and hedge funds own 77.35% of the company's stock.

FibroGen Company Profile

(Get Rating)

FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States, Europe, China, and Japan; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes.

Further Reading

  • Get a free copy of the StockNews.com research report on FibroGen (FGEN)
  • Look at Honeywell for a Steady and Diversified Stock
  • Why Invest in High-Yield Dividend Stocks?
  • Find and Profitably Trade Stocks at 52-Week Lows
  • Disney (NYSE: DIS) Shares Just Gave Investors A Massive Signal
  • Solar Stocks Shine Brightly After Passage Of Clean Energy Bill

Receive News & Ratings for FibroGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen and related companies with MarketBeat.com's FREE daily email newsletter.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment